Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.
Yaturu
Subhashini
S
Department of Endocrinology, Overton Brooks VA Medical Center, Shreveport, Louisiana 71101-4295, USA. subhashini.yaturu@med.va.gov
Bryant
Barbara
B
Jain
Sushil K
SK
D015519:Bone Density / Q000187:drug effects*; D001862:Bone Resorption / Q000139:chemically induced*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology*; D050723:Fractures, Bone / Q000453:epidemiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; C089946:2,4-thiazolidinedione